overview of the striatum - national institute on drug ... · overview of the striatum. dorsal. ......
TRANSCRIPT
Overview of the striatum
dorsal
ventral
•Dorsal striatum important for motor planning and adaptive behaviors. Main inputs arise from motor cortex.
•Disorders involving dorsal striatum include Parkinson’s disease and Huntington’s disease.
•Ventral striatum (nucleus accumbens) is important for reward. Main inputs arise from amygdala and prefrontal cortex.
•Drug addiction, depression are disorders involving the striatum.
Neurotransmission and neuromodulation:• Adrenaline (ca. 1900-) • Acetylcholine (ca. 1900-)• Neuropeptides (1930-)• Amino Acids (GABA and Glutamate) (1950-)• Monoamines (5-HT and Dopamine) (1950-)• Endogenous opioids (1975-) • Endogenous cannabinoids (1992-)
-CB1 receptor cloned (1990)-discovery of endogenous endocannabinoids (1992)-modulation of synaptic function (2001)
Egertova and Elphick, J Comp Neurology (2000)
CB1 immunoreactivity
Gerdeman et al., Nat Neurosci (2002)
Corticostriatal LTD
Endocannabinoid signaling in the striatum
Anatol KreitzerSheela Singla
Brad Grueter
Percy Luu
• Acute coronal brain slices – recordings performed from medium spiny neurons (MSNs) in dorsolateral striatum of 3- to 4-week-old rats and mice
• CsMeSO3 based-internal solution, 0.2 mM EGTA, QX-314 to block Na currents
• External saline: 2 mM Ca, 1 mM Mg. Picrotoxin (50 μM) present to block GABAA-mediated currents.
• Experiments performed at room temperature (RT) and 30-32 °C
Experimental Methods
100
50
0
EP
SC
(% b
asel
ine)
403020100
control (n=15) AM251 (n=6)
Tetanus induces endocannabinoid-mediated LTD(eCB-LTD)
Time (min)
100
50
0
EP
SC
(% b
asel
ine)
403020100Time (min)
LY341495 (n=5)
eCB-LTD requires mGluRs
100
50
0
EP
SC
(% b
asel
ine)
403020100Time (min)
hp:-50 (n=11) hp: -50, AM251 (n=5)
DHPG (100 uM)
Endocannabinoids are released by activation of postsynaptic mGluRs
sulpiride=D2 antagonist
eCB-LTD requires D2 receptors
100
50
0403020100
Time (min)
sulpiride (n=5)
EP
SC
(% b
asel
ine)
1. mGluR activation, combined with subthreshold depolarization, leads to endocannabinoid (eCB) synthesis and release
2. Dopamine D2 receptor activation enhances eCB synthesis, while D2 inhibition reduces eCB synthesis
3. Released eCBs bind to presynaptic CB1 receptors and induce presynaptic LTD
4. Neurotransmitter release is reduced for tens of minutes or more
(Kreitzer and Malenka, 2005)
Model of endocannabinoid release and LTD in the striatum
dorsal
ventral
The striatum is not homogeneous (2 populations of medium spiny neurons)
Caudate/Putamen
Motor Cortex
MotorThalamus
PremotorCortex
Glutamate
GABA
GPeGPi/SNr
STN
Dopamine
SNc
+
Direct pathway MSNs express:Dopamine D1 receptors, MuscarinicM4 receptors, Dynorphin, Substance P
Basal ganglia motor circuit: direct pathway
Caudate/Putamen
Motor Cortex
MotorThalamus
PremotorCortex
Glutamate
GABA
GPeGPi/SNr
STN
Dopamine
SNc
-
Indirect pathway MSNs express:Dopamine D2 receptors, Enkephalin
Basal ganglia motor circuit: indirect pathway
Basal ganglia motor circuit: Parkinson disease
Striatum
Motor Cortex
MotorThalamus
PremotorCortex
+ Glutamate
- GABA
GPeGPi/SNr
STN
Dopamine
SNc
+
-
X
NAc
VP
VTA/Substantia Nigra
mPFC
BLAVentral Subiculum
D1 D2
Nucleus accumbens direct and indirect pathways?
12 3
1. CPu2. GPe3. SNr
M4-GFP
D2-GFP
M4- and D2-GFP BAC-transgenic mice label direct and indirect pathway medium spiny neurons
GENSAT Program (N. Heintz, M. Hatten, W. Yang)
2.0
1.5
1.0A2/
A1
5002500ISI (ms)
2.0
1.5
1.0A2/
A1
5002500ISI (ms)
1.5
1.0A2/
A1
5002500ISI (ms)
direct (D2-)indirect (D2+)
1.5
1.0
A2/
A1
5002500ISI (ms)
direct (M4+)indirect (M4-)
D2+
200 pA50 ms
M4+
200 pA50 ms
Aa Ab
Ba Bb
Direct and indirect pathway synapses display different paired-pulse ratios
1.0
0.5
0.0
Cum
. Pro
b.
210Inter-event Interval (s)
1.0
0.5
0.0
Cum
. Pro
b.
500Amplitude (pA)
20
10
0
Mea
n A
mp
(pA
)
4
2
0
Mea
n Fr
eq (H
z)
A B C
20 pA0.2 s
Direct Indirect
D I D I
(4)
(5) (4) (5)
Indirect pathway synapses have a higher release probability
0 100 2000.5
1.0
1.5
PP
R
Interstim interval (msec)
D2(+) D2(-)
Direct and indirect pathway synapses display different paired-pulse ratios in nucleus accumbens
0
1
2
3
4
5
6
7
D2(-)D2(+)
*
Ave
rage
mE
PS
C F
requ
ency
(Hz)
0
5
10
15
20
25
D2(-)D2(+)Ave
rage
mE
PS
C A
mpl
itude
(pA
)
Indirect (D2+) pathway synapses have a higher release probability in nucleus accumbens?
40
20
0
Freq
(Hz)
4002000I (pA)
directindirect
2
1
0ISI (
norm
.)
100Spike #
directindirect
Aa Ab B
C
Direct Indirect
20 mV
100 ms
Indirect pathway medium spiny neurons are more excitable
0 100 200 300 4000
5
10
15
20
25
30
**
Freq
uenc
y (H
z)I (pA)
D2(+) D2(-)
Indirect (D2+) pathway medium spiny neurons are more excitable in nucleus accumbens
Direct Indirect
100
50
0
EPSC
(% b
asel
ine)
403020100
direct (D2 neg) (n=8)indirect (D2 pos) (n=6)
Endocannabinoid-mediated LTD occurs only at indirect pathway synapses
Time (min)
0 10 20 30 400
50
100
150
EP
SC
Am
plitu
de (%
Bas
elin
e)
Time (min)
D2(-)
0 10 20 30 400
50
100
150
EP
SC
Am
plitu
de (%
Bas
elin
e)
Time (min)
D2(+)
Endocannabinoid-mediated(?) LTD occurs only at indirect pathway synapses in nucleus accumbens
Indirect pathway eCB-LTD requires dopamine D2 receptor activation
100
50
0
EPSC
(% b
asel
ine)
40200Time (min)
AM251sulpiride5-HT, NE antagonists
AM251: cannabinoid CB1 receptor antagonistsulpiride: dopamine D2 receptor antagonist
CB1 receptor agonists inhibit transmitter release at both direct and indirect pathway
synapses
100
50
0
EP
SC
(% b
asel
ine)
40200Time (min)
WINAM251
directindirect
WIN55,212: cannabinoid CB1 receptor agonistAM251: cannabinoid CB1 receptor antagonist
Postsynaptic mGluR-driven endocannabinoid release occurs primarily at indirect pathway
synapses
100
50
0
EPSC
(% b
asel
ine)
40200Time (min)
DHPG
directindirect
0 10 20 30 40 50 600
50
100
150
100μM RS-DHPG
EP
SC
Am
plitu
de (%
Bas
elin
e)
Time (min)
D2(-)
0 10 20 30 40 50 600
50
100
150
100μM RS-DHPG (-50mV)
EP
SC
Am
plitu
de (%
Bas
elin
e)Time (min)
D2(+) (-50mV)
Postsynaptic mGluR-driven LTD occurs primarily at indirect pathway synapses in nucleus accumbens
Indirect pathway eCB-LTD is absent in an animal model of Parkinson disease
100
50
0
EP
SC
(% b
asel
ine)
40200
indirect (n=6)indirect, reserpine treated (n=7)
Time (min)
Calcium
Phosphatidylethanolamine (PE)
N-arachidonoyl PE
N-Acyltransferase
FAAH
Arachidonic acid Ethanolamine+
MGL
Arachidonic acid + glycerol
Calcium
Phosphatidylinositol (PI)
Diacylglycerol (DAG)
Phospholipase CβReceptor activation(mGluR or mAChR)
NAPE-PLD
Anandamide (AEA)
DAG Lipase
2-arachidonoylglycerol (2-AG)
Calcium
Endocannabinoid biosynthesis and inactivation
(URB754)(URB597)
quinpirole: dopamine D2 receptor agonistURB754: monoacylglycerol lipase (MGL) inhibitorURB597: FAAH inhibitor
Rescue of indirect pathway LTD in a Parkinson’s disease model (reserpine)
100
50
040200
Time (min)
reserpine-treated, quinpirole (n=5)reserpine-treated, URB754 (n=6)
EPSC
(% b
asel
ine) 100
50
0
EP
SC
(% b
asel
ine)
40200Time (min)
reserpine, URB597
quinpirole: dopamine D2 receptor agonistURB597: FAAH inhibitor
Rescue of indirect pathway LTD in a Parkinson’s disease model (6-OHDA)
150
100
50
0
EP
SC
(% b
asel
ine)
40200Time (min)
6-OHDA6-OHDA, quinpirole
100
50
0
EPS
C (%
bas
elin
e)
40200
Time (min)
6-OHDA, URB597
An important role for dopamine D2 receptors and cannabinoid CB1 receptors in movement
wt D2 -/- wt D2 -/-
D2 -/- mousecatalepsy Locomotor activity
Baik et al. (1995), Nature
CB1 -/- mouse
Zimmer et al. (1999), PNAS
D2-/-wt
Inhibition of eCB degradation enhances D2-receptor- mediated recovery from catalepsy in animal models
of Parkinson disease
Inhibition of eCB degradation enhances D2-receptor- mediated recovery of locomotor activity in animal
models of Parkinson disease
Caudate/Putamen
Motor Cortex
MotorThalamus
PremotorCortex
+ Glutamate
- GABA
GPeGPi/SNr
STN
Dopamine
SNc
+
-
X
(L-DOPA)
STN Pacemaker
Pallidotomy
eCB biosynthesis
Basal ganglia motor circuit: Parkinson’s disease treatments
Conclusions•
eCB-LTD in the striatum is restricted to indirect
pathway cells
•
it is synapse specific because it requires presynaptic activity in addition to CB1 receptor activation
•
eCB-LTD is prevented by dopamine depletion but can be rescued by a D2 agonist and an inhibitor of eCB
degradation
•
inhibition of eCB
degradation improves motor performace
in animals models of Parkinson
disease
•
D2(+) and D2(-) cells in the accumbens
also have different synaptic properties
Anatol KreitzerSheela Singla
Brad Grueter
Percy Luu
Nathaniel Heintz (Rockefeller)
X. William Yang (UCLA)
LTD
LTD?
cannabinoids
Is presynaptic eCB-LTD activity-dependent?
-Spillover onto synapses that did not participate in depolarizing the postsynaptic cell could cause LTD.
-Synapse specificity may be achieved if LTD depended on presynaptic activity and not just receptor activation.
pathway 1: no synaptic stimulation
pathway 2: 0.05 Hz-1 Hzsynaptic stimulation
Testing the effect of synaptic activity on LTD
100
50
0EPS
C (%
bas
elin
e)
40200
Time (min)
100
50
040200
Time (min)
A B
striatum
WINAM251 WIN AM251
cerebellum
A CB1 agonist is sufficient to induce LTD in the striatum, but not the cerebellum
10 min WIN 20 min WIN
WIN-induced LTD is activity-dependent
path 1, path 2
eCB-LTD is activity-dependent
Mallet et al (2006) J Neurosci
(direct) (indirect)
Imbalanced activity in striatal motor circuits in vivo in a Parkinson disease model
100
50
0
EP
SC
(% b
asel
ine)
3020100
Time (min)
pirenzepine
hp: -70 mV hp: -50 mV
100
50
040200
Time (min)
sulpiridesulpiride and pirenzepine
A B 100 Hz tetanus
pirenzepine: muscarinic M1 receptor antagonistsulpiride: dopamine D2 receptor antagonist
Muscarinic M1 receptors do not regulate striatal endocannabinoid release or eCB-LTD
1.5
1.0
PPR
5002500ISI (ms)
indirect (D2+)indirect (D2+), dopamine-depleted 100
50
0
EP
SC
(% b
asel
ine)
40200Time (min)
WINAM251
dopamine-depleted
Dopamine-depleted mice do not have altered paired-pulse plasticity or sensitivity to cannabinoids
0.6
0.4
0.2
0.0N
MD
A/A
MPA
ratio
A
100 pA
20 ms
direct
indirect
direct indirect
A
A1
2
3 *
Indirect pathway synapses have larger NMDA/AMPA current ratios
Inhibition of eCB degradation enhances D2-receptor- mediated recovery from catalepsy in animal models
of Parkinson disease
Inhibition of eCB degradation enhances D2-receptor- mediated recovery of locomotor activity in animal
models of Parkinson disease
Signaling through CB1 receptors
Adapted from DiMarzo et al., Nature Reviews Drug Discovery (2004)
heterotrimeric G-protein
CB1R
agonist
Anandamide (endogenous agonist)
2-AG (endogenous agonist)
THC (partial agonist)
Endocannabinoid biosynthesis and inactivation
Calcium
Phosphatidylethanolamine (PE)
N-arachidonoyl PE
N-Acyltransferase
FAAH
Arachidonic acid Ethanolamine+
MGL
Arachidonic acid + glycerol
Calcium
Phosphatidylinositol (PI)
Diacylglycerol (DAG)
Phospholipase CβReceptor activation(mGluR or mAChR)
NAPE-PLD
Anandamide (AEA)
DAG Lipase
2-arachidonoylglycerol (2-AG)
Calcium
Inhibition of endocannabinoid degradation enhances D2-receptor-mediated recovery of movement in a
Parkinson disease model
40
20
0Des
cent
Lat
ency
(s) 800
400
0Dis
tanc
e Tr
avel
ed (c
m)
A BCatalepsy Locomotor Activity
rese
rpin
e-tre
ated
+ qu
inpi
role
+ qu
inpi
role
/UR
B75
4*
+ U
RB7
54
rese
rpin
e-tre
ated
+ qu
inpi
role
+ qu
inpi
role
/UR
B75
4
+ U
RB7
54
120 *
D2 receptor activation enhances endocannabinoid release in response to brief
mGluR activation
100
50
0
EPS
C (%
bas
elin
e)
3020100Time (min)
controlquinpirole
DHPG
Signaling through CB1 receptors
agonistheterotrimeric G-protein
THC (partial agonist)
2-AG (endogenous agonist)
Anandamide (endogenous agonist)
Adapted from DiMarzo et al., Nature Reviews Drug Discovery (2004)
Calcium
Phosphatidylethanolamine (PE)
N-arachidonoyl PE
N-Acyltransferase
FAAH
Arachidonic acid Ethanolamine+
MGL
Arachidonic acid + glycerol
Calcium
Phosphatidylinositol (PI)
Diacylglycerol (DAG)
Phospholipase CβReceptor activation(mGluR or mAChR)
NAPE-PLD
Anandamide (AEA)
DAG Lipase
2-arachidonoylglycerol (2-AG)
Calcium
Endocannabinoid biosynthesis and inactivation
(URB754)(URB597)
CB1 receptor distribution in rat brain
(from Pettit et al., 1998)
100
50
0
EP
SC
(% b
asel
ine)
100500-50
1 sec depol (n=4)
5 sec depol (n=3)
A
10 ms
200 pA
( ) control
( ) control
t=10 sΔ
t=10 sΔ
Endocannabinoids are not released by medium spiny neuron depolarization
DHPG (100 uM)
mGluR-mediated endocannabinoid release requires L-type calcium channels
100
50
0403020100
Time (min)
hp:-50 (n=11) hp:-50, nitrendipine (n=8)
EPSC
(% b
asel
ine)
DHPG (100 uM)
mGluR-mediated endocannabinoid release is enhanced by subthreshold depolarization
100
50
0403020100
hp: -70 (n=9) hp: -50 (n=11)
Time (min)
EPSC
(% b
asel
ine)
Down state: -60 to –90 mVcalcium influx mediated by T- and R-type VSCCs
Up state: -40 to –70 mV,calcium influx mediated by L- and R-type VSCCs
Wilson and Kawaguchi (1996), J NeurosciCarter and Sabatini (2004), Neuron
Stern et al.(1998), Nature
Medium spiny neurons: up and down states
Mallet et al (2006) J Neurosci
(direct) (indirect)
Imbalanced activity in striatal motor circuits in vivo in a Parkinson disease model